 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 December 1998 | Volume 129 Issue 12 | Pages 1031-1035
Background: Immunoablative high-dose cyclophosphamide without stem-cell rescue induces durable, complete remission in most patients with aplastic anemia.
Objective: To determine the efficacy of high-dose cyclophosphamide in various refractory, severe autoimmune diseases.
Design: Prospective phase II study.
Setting: Johns Hopkins University (Baltimore, Maryland) and Hahnemann University (Philadelphia, Pennsylvania).
Patients: Eight patients with refractory, severe autoimmune disease.
Intervention: Immunoablative high-dose cyclophosphamide (50 mg/kg of body weight per day) for 4 consecutive days.
Measurements: Clinical and laboratory variables of autoimmune disease.
Results: Seven patients improved markedly: Five achieved complete remission and two achieved partial remission. Four patients have remained in continuous complete remission for 3 to 21 months, and two patients in partial remission continue to improve after 14 and 19 months of follow-up. High-dose cyclophosphamide was well tolerated; median times to a neutrophil count of 0.5 x 109 cells/L and platelet transfusion independence were 17 and 16 days, respectively.
Conclusions: Immunoablative high-dose cyclophosphamide without stem-cell rescue can induce complete remission in patients with refractory, severe autoimmune disease. Reemergence of marrow function is similar to that seen after autologous transplantation and does not carry the risk for reinfusion of autoaggressive lymphocytes with the autograft.
Author and Article Information
From Johns Hopkins University School of Medicine, Baltimore, Maryland; and Hahnemann University, Philadelphia, Pennsylvania.
BRIEF COMMUNICATION
Immunoablative High-Dose Cyclophosphamide without Stem-Cell Rescue for Refractory, Severe Autoimmune Disease
Acknowledgments: The authors thank Chriscinthia Blount for assistance in manuscript preparation; Phillip Seaman for providing excellent clinical care; and the patient coordinator, Donna Dorr, for help with patient accrual.
Grant Support: In part by National Institutes of Health grants CA15396, CA70970, and AR43727. Dr. R.A. Brodsky is an American Society of Hematology Junior Faculty Scholar.
Requests for Reprints: Robert A. Brodsky, MD, Johns Hopkins Oncology Center, Room 2-127, 600 North Wolfe Street, Baltimore, MD 21287-8967.
Current Author Addresses: Dr. R.A. Brodsky, Dr. Smith, Dr. Seifter, and Dr. Jones: Johns Hopkins Oncology Center, Room 2-127, 600 North Wolfe Street, Baltimore, MD 21287-8967.
This article has been cited by other articles:
|
|
 |
|
  C. Krishnan, A. I. Kaplin, R. A. Brodsky, D. B. Drachman, R. J. Jones, D. L. Pham, N. D. Richert, C. A. Pardo, D. M. Yousem, E. Hammond, et al. Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis Arch Neurol, August 1, 2008; 65(8): 1044 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C V Tehlirian, L K Hummers, B White, R A Brodsky, and F M Wigley High-dose cyclophosphamide without stem cell rescue in scleroderma Ann Rheum Dis, June 1, 2008; 67(6): 775 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Smith-Berdan, D. Gille, I. L. Weissman, and J. L. Christensen Reversal of autoimmune disease in lupus-prone New Zealand black/New Zealand white mice by nonmyeloablative transplantation of purified allogeneic hematopoietic stem cells Blood, August 15, 2007; 110(4): 1370 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Gladstone, K. W. Zamkoff, L. Krupp, R. Peyster, P. Sibony, C. Christodoulou, E. Locher, and P. K. Coyle High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis Arch Neurol, October 1, 2006; 63(10): 1388 - 1393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Petri and R. Brodsky High-Dose Cyclophosphamide and Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus JAMA, February 1, 2006; 295(5): 559 - 560. [Full Text] [PDF]
|
|
|
|
|
|
B Maurer, M Hensel, R Max, C Fiehn, A D Ho, and H M Lorenz Autologous haematopoietic stem cell transplantation for Behcet's disease with pulmonary involvement: analysis after 5 years of follow up Ann Rheum Dis, January 1, 2006; 65(1): 127 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. Ortel Thrombosis and the Antiphospholipid Syndrome Hematology, January 1, 2005; 2005(1): 462 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Petri Cyclophosphamide: new approaches for systemic lupus erythematosus Lupus, May 1, 2004; 13(5): 366 - 371. [Abstract] [PDF]
|
|
|
|
|
|
P I Sidiropoulos and D T Boumpas Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients Lupus, May 1, 2004; 13(5): 391 - 397. [Abstract] [PDF]
|
|
|
|
|
|
G. Rossi, A. Moretta, and F. Locatelli Autologous hematopoietic stem cell transplantation for severe/refractory intestinal Behcet disease Blood, January 15, 2004; 103(2): 748 - 750. [Full Text] [PDF]
|
|
|
|
|
|
C P Mavragani and H M Moutsopoulos Lupus nephritis: current issues Ann Rheum Dis, September 1, 2003; 62(9): 795 - 798. [Full Text] [PDF]
|
|
|
|
|
|
C C Mok, R W S Wong, and K N Lai Treatment of severe proliferative lupus nephritis: the current state Ann Rheum Dis, September 1, 2003; 62(9): 799 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Storb, G. Lucarelli, P. A. McSweeney, and R. W. Childs Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors Hematology, January 1, 2003; 2003(1): 372 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Huhn, P. F. Fogarty, R. Nakamura, E. J. Read, S. F. Leitman, M. E. Rick, J. Kimball, A. Greene, K. Hansmann, A. Gratwohl, et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia Blood, January 1, 2003; 101(1): 71 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D D'Cruz High-dose intravenous cyclophosphamide therapy in severe SLE Lupus, July 1, 2002; 11(7): 403 - 404. [PDF]
|
|
|
|
|
|
D E Gladstone, A A Prestrud, A Pradhan, M J Styler, D L Topolsky, P A Crilley, S Hoch, A Huppert, and I Brodsky High-dose cyclophosphamide for severe systemic lupus erythematosus Lupus, July 1, 2002; 11(7): 405 - 410. [Abstract] [PDF]
|
|
|
|
|
|
V. M. Moyo, D. Smith, I. Brodsky, P. Crilley, R. J. Jones, and R. A. Brodsky High-dose cyclophosphamide for refractory autoimmune hemolytic anemia Blood, June 28, 2002; 100(2): 704 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.H. Brannagan III, A. Pradhan, T. Heiman-Patterson, A.C. Winkelman, M.J. Styler, D.L. Topolsky, P.A. Crilley, R.J. Schwartzman, I. Brodsky, and D.E. Gladstone High-dose cyclophosphamide without stem-cell rescue for refractory CIDP Neurology, June 25, 2002; 58(12): 1856 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Houssiau and M. Jadoul Cytotoxic therapy of lupus nephritis: recent developments Nephrol. Dial. Transplant., June 1, 2002; 17(6): 955 - 957. [Full Text] [PDF]
|
|
|
|
|
|
R. K. Burt, S. Slavin, W. H. Burns, and A. M. Marmont Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood, February 1, 2002; 99(3): 768 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A M Marmont Lupus: tinkering with haematopoietic stem cells Lupus, November 1, 2001; 10(11): 769 - 774. [PDF]
|
|
|
|
 |
|
 R. A. Brodsky, L. L. Sensenbrenner, B. D. Smith, D. Dorr, P. J. Seaman, S. M. Lee, J. E. Karp, I. Brodsky, and R. J. Jones Durable Treatment-Free Remission after High-Dose Cyclophosphamide Therapy for Previously Untreated Severe Aplastic Anemia Ann Intern Med, October 2, 2001; 135(7): 477 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Illei, H. A. Austin III, M. Crane, L. Collins, M. F. Gourley, C. H. Yarboro, E. M. Vaughan, T. Kuroiwa, C. L. Danning, A. D. Steinberg, et al. Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis Ann Intern Med, August 21, 2001; 135(4): 248 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Anhalt and L. A. Diaz Research Advances in Pemphigus JAMA, February 7, 2001; 285(5): 652 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Petri The egg and I: preserving fertility in systemic lupus erythematosus Lupus, July 1, 2000; 9(6): 399 - 400. [PDF]
|
|
|
|
|
|
K. M. Sullivan, R. Parkman, and M. C. Walters Bone Marrow Transplantation for Non-Malignant Disease Hematology, January 1, 2000; 2000(1): 319 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Burt and A. E. Traynor Hematopoietic Stem Cell Transplantation: A New Therapy for Autoimmune Disease Stem Cells, November 1, 1999; 17(6): 366 - 372. [Full Text]
|
|
|
|
 |
|
 C. Aristei and A. Tabilio Total-Body Irradiation in the Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoproliferative Diseases Oncologist, October 1, 1999; 4(5): 386 - 397. [Abstract] [Full Text]
|
|
|
|
|
|
D J Wallace Apheresis for lupus erythematosus Lupus, March 1, 1999; 8(3): 174 - 180. [Abstract] [PDF]
|
|
|
|
|
|
R. K. Burt and A. E. Traynor Hematopoietic Stem Cell Transplantation: A New Therapy for Autoimmune Disease Oncologist, February 1, 1999; 4(1): 77 - 83. [Full Text]
|
|
Article
